Human Reproduction, Vol. 10, No. 6, pp. 1392-1396, 1995
© 1995 European Society of Human Reproduction and Embryology
Randomized controlled trial of follicle stimulating hormone versus human menopausal gonadotrophin in in-vitro fertilization*
1 Departments of Obstetrics and Gynecology, McMaster University 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada 2 Clinical Epidemiology and Biostatistics, McMaster University 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
Correspondence: 3To whom correspondence should be addressed at Department of Obstetrics and Gynecology, McMaster University, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
The adverse effect of raised luteinizing hormone (LH) concentrations on reproductive outcome suggests that exogenous LH administration for ovarian stimulation may not be desirable. The aim of this study was to compare the clinical pregnancy rates between follicle stimulating hormone (FSH) and human menopausal gonadotrophin (HMG) used in in-vitro fertilization (IVF) cycles. A total of 232 infertile patients, with a mean duration of infertility of 67.1 ± 32.9 months, were selected for IVF (female age <38 years, FSH <15 IU/1, and total motile sperm count >5x106). A short (flare-up) protocol with daily leuprolide acetate was followed randomly from day 3 with FSH (n = 115) or human menopausal gonadotrophin (HMG; n = 117), at an initial dose of two ampoules per day. A maximum of three embryos was transferred, and the luteal phase was supported with four doses of HCG (2500 IU). No differences were observed between the two groups in any of the cycle response variables except fertilization rates per oocyte and per patient, both of which were significantly higher with FSH. Clinical pregnancy rates per cycle initiated, per oocyte retrieval and per embryo transfer were 19.1, 21.0 and 22.7% respectively for FSH, and 12.0, 12.8 and 15.4% respectively for HMG. Whilst these differences were not statistically significant, the results of this interim analysis suggest that HMG may be associated with a lower clinical pregnancy rate than FSH.
Key words: gonadotrophins/gonadotrophin-releasing hormone agonist/in-vitro fertilization/infertility/randomized controlled trial
Submitted on December 6, 1994; accepted on March 13, 1995.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Kilani, A. Dakkak, S. Ghunaim, G.E. Cognigni, C. Tabarelli, L. Parmegiani, and M. Filicori A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes Hum. Reprod., June 1, 2003; 18(6): 1194 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Check HMG is possibly superior to recombinant FSH for IVF Hum. Reprod., November 1, 2001; 16(11): 2473 - 2473. [Full Text] [PDF]
|
|
|
|
|
|
S. Daya and J. Gunby Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Hum. Reprod., September 1, 1999; 14(9): 2207 - 2215. [Abstract] [Full Text] [PDF]
|
|